STOCK TITAN

FENC Form 144 Notice — 1,775 Shares to Trade on NASDAQ 10/10/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on 10/10/2025 on NASDAQ. The filing shows the shares were acquired the same day, 10/10/2025, by stock option exercise from the issuer and paid in cash. There were 27,831,698 shares outstanding noted for the class. No securities were reported sold in the prior three months. The filer affirms they are not aware of undisclosed material adverse information and the notice contains the standard attestation language regarding trading plans and criminal penalties for false statements.

Positive

  • Full disclosure of proposed sale details including broker, share count, value, and planned sale date
  • Acquisition method transparently stated as a stock option exercise with cash payment on 10/10/2025
  • No prior sales reported in the past three months for the selling person

Negative

  • None.

Insights

Small post‑exercise sale planned by an insider via market broker.

The notice records a proposed open‑market sale of $16,401.00 for 1,775 shares to be executed through Morgan Stanley Smith Barney LLC on 10/10/2025. The shares were acquired by a stock option exercise and paid in cash on the same date, which indicates an immediate post‑exercise disposition rather than a long‑term transfer.

This transaction size represents a small fraction of the class base (27,831,698 outstanding), so it is unlikely to be price‑moving alone. Monitor trade execution on the listed exchange around 10/10/2025 for any clustering with other insider sales that could be material.

Filing follows Rule 144 disclosure and includes standard attestation.

The form includes the required representation that the seller is unaware of any undisclosed material adverse information and notes the possibility of a Rule 10b5‑1 trading plan if applicable. It names the executing broker and furnishes acquisition details (exercise from the issuer, cash payment).

From a compliance perspective, the clear dating of acquisition and planned sale simplifies rule‑144 eligibility review. If a trading plan or instruction date exists, it should be noted to confirm affirmative safe‑harbor timing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by FENC report?

It reports a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00, to be sold approximately on 10/10/2025 on NASDAQ.

How were the shares being sold acquired according to the filing?

The shares were acquired on 10/10/2025 by a stock option exercise from the issuer and paid for in cash.

Who is the broker named for the planned sale in the FENC Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza.

Does the filing indicate recent sales by the same person?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How many shares outstanding does the filing show for the class?

The filing lists 27,831,698 shares outstanding for the class.
Fennec Pharmaceuticals Inc

NASDAQ:FENC

FENC Rankings

FENC Latest News

FENC Latest SEC Filings

FENC Stock Data

267.08M
28.29M
16.25%
57.88%
4.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RESEARCH TRIANGLE PARK